by | Dec 18, 2019 | Gutmann, David
— Using a series of Nf1 genetically-engineered mouse strains, researchers isolated low-grade glioma stem cells (CD133+ cells) for in vitro and in vivo brain tumor studies. These lines are authenticated optic glioma stem cells, with the ability to self-renew at limiting dilutions; express stem cell mar…
by | Dec 16, 2019 | Wang, Xiaowei
— Technology Description
In search of more effective cancer treatments, inventors in Dr. Xiaowei Wang’s lab at Washington University School of Medicine have developed artificial interference RNA (aiRNA). aiRNA is a patented chimeric RNAi that combines the multi-target abilities of miRNAs and t…
by | Dec 5, 2019 | Pachynski, Russell
— Disease indication – cancer, particularly lung, breast, colon, and prostate cancer or melanoma (cancers where chemerin is down-regulated at the tumor site)
Drug format – engineered fusion protein
Drug class – first in class
Research stage and Preliminary data
Target &ndash…
by | Nov 27, 2019 | Murphy, Kenneth
— Irf8 Delta32 mice have a CRISPR targetted deletion in the enhancer of the mouse Irf8 gene located at +32 kilobases from the Irf8 gene promoter. This deletion removes the binding site for the Jun/Batf3/Irf8 complex and results in a complete and permanent elimination of the development of the cDC1 lin…
by | Nov 25, 2019 | Henderson, Jeffrey P.
— Technology Description
Researchers in Prof. Jeffrey Henderson’s laboratory have discovered a drug target and a class of small molecule candidates that could be used to selectively prevent pathogenic enterobacteria from causing diseases such as urinary tract infections (UTIs).
Currently, UTI…